Key Details
Price
$18.56Last Dividend
$0.01Annual Revenue
$509.79 MAnnual EPS
$0.77Annual ROE
17.52%Beta
-Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 23, 2024Recent annual earnings:
Jan 31, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 04, 2024Next split:
N/ARecent split:
July 09, 2010Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables.
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024.
Core Laboratories Inc. (NYSE:CLB ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants Sean Mitchell - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Lab Q3 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.
Energy stocks such as PUMP, CLB and OII are poised to deliver a Q3 earnings beat.
CLB is expected to report higher revenues compared with the previous quarter, along with reduced costs for services and product sales and general administrative expenses.
Core Laboratories (CLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CLB is a compelling investment in the oilfield services sector, featuring strong fundamentals, innovative technologies and a disciplined financial strategy poised for growth.
Considering OPEC's optimistic oil demand growth forecast, we recommend buying stocks like CLB, FTI and TUWOY.
FAQ
- What is the primary business of Core Laboratories NV?
- What is the ticker symbol for Core Laboratories NV?
- Does Core Laboratories NV pay dividends?
- What sector is Core Laboratories NV in?
- What industry is Core Laboratories NV in?
- What country is Core Laboratories NV based in?
- When did Core Laboratories NV go public?
- Is Core Laboratories NV in the S&P 500?
- Is Core Laboratories NV in the NASDAQ 100?
- Is Core Laboratories NV in the Dow Jones?
- When was Core Laboratories NV's last earnings report?
- When does Core Laboratories NV report earnings?
- Should I buy Core Laboratories NV stock now?